Expanding the Functionality and Target Spectrum of Kinase Inhibitors using PROTACs
Expanding the Functionality and Target Spectrum of Kinase Inhibitors using PROTACs
批准号:
496561415
负责人:
Professor Dr. Stefan Knapp
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:
中文摘要
激酶抑制剂是广泛使用的药物,显著改善了癌症患者的预后。然而,由于抑制剂没有达到基因实验提出的期望,或者它们与无法耐受的毒性有关,许多激酶或与激酶相关的蛋白仍然是靶点。到目前为止,用ATP竞争性抑制剂对一种激酶的常规抑制还没有导致临床上的成功的一个例子是Aurora-A激酶。Aurora-A在肿瘤发生中起着核心作用,遗传数据表明许多肿瘤严重依赖Aurora-A生长,这使它成为治疗癌症Aurora-A的有力证据。不幸的是,所有使用Aurora-A激酶抑制剂的临床试验都没有明显的疗效,但毒性有限,许多试验已经提前终止。因此,目前还没有针对Aurora-A的靶向药物。由于许多报道表明Aurora-A在肿瘤细胞中也具有非催化作用,我们探索了一类新的小分子称为蛋白水解靶向嵌合体(PROTACs)对Aurora-A的抑制作用。PROTAC不是抑制催化活性,而是将靶点招募到细胞E3泛素连接酶上,从而诱导蛋白酶体降解,从而也解决了非催化蛋白质的功能。我们最近开发了一种PROTAC,可以在白血病细胞中诱导Aurora-A的快速和特异性降解。值得注意的是,这种工具化合物引起S期阻滞和大量细胞凋亡,这与Aurora-A激酶抑制剂的细胞作用明显不同。虽然这些结果开辟了一条针对癌症治疗中Aurora-A支架功能的新途径,但开发的PROTAC也提供了一个通用的工具来研究Aurora-A功能及其与信号伙伴的中介相互作用。基于我们的初步数据,我们现在将开发Aurora-A PROTAC,用于体内小鼠模型,以探索Aurora-A降解在癌症治疗中的潜力。我们将在我们的Aurora-ProTAC-Cereblon三元络合物模型的基础上改进该化合物的药代动力学。我们将使用这种优化的PROTAC来探索Aurora-A PROTAC在临床前白血病模型中的有效性和安全性。同时,我们将使用我们的化合物来更好地了解Aurora-A调节细胞周期的支架作用。在第二条实验中,我们将为有希望的癌症靶点RUVBL1和RUVB2开发PROTAC。作为Aurora-A,RUVBL蛋白直接与癌基因蛋白MYC结合,对MYC的致癌功能是不可或缺的。此外,又一次类似于Aurora-A,这两种蛋白质都结合和水解三磷酸腺苷,但具有独立于其催化活性的额外的重要致癌功能。在我们使用Aurora-A PROTAC经验的基础上,我们将设计、合成和表征RUVBL1/2 PROTAC,并在白血病模型中测试它们的抗癌性能。
英文摘要
Kinase inhibitors are widely used drugs that have significantly improved the prognosis of cancer patients. However, many kinases or kinase-related proteins remain to be targeted, as inhibitors did not meet the expectations raised by genetic experiments or they have been associated with intolerable toxicity. An example where conventional inhibition of a kinase by ATP competitive inhibitors has not led to clinical success so far is the Aurora-A kinase. Aurora-A plays a central role in tumorigenesis and genetic data have demonstrated that many tumours critically depend on Aurora-A for growth, making this a compelling case for therapeutic targeting of Aurora-A in cancer. Unfortunately, all clinical trials with Aurora-A kinase inhibitors showed no significant therapeutic effect, but dose-limiting toxicity, and many trials have been terminated prematurely. Therefore, no Aurora-A-targeting drugs are currently available.As many reports indicate also a non-catalytic function of Aurora-A in tumour cells, we explored the inhibition of Aurora-A by a new class of small molecules called proteolysis targeting chimeras (PROTACs). Instead of inhibiting the catalytic activity, PROTACs recruit targets to cellular E3 ubiquitin ligases and thereby induce proteasomal degradation, thus also addressing non-catalytic protein functions. We recently developed a PROTAC that induced rapid and specific degradation of Aurora-A in leukaemia cells. Strikingly, this tool compound caused S phase arrest and rampant apoptosis, which is markedly different from the cellular effects of Aurora-A kinase inhibitors. While these results open a new avenue to target Aurora-A scaffolding function in cancer therapy, the developed PROTACs also provide a versatile tool to study Aurora-A function and its mediated interaction with signalling partners. Based on our preliminary data, we will now develop the Aurora-A PROTAC for in vivo use in mouse models to explore the potential of Aurora-A degradation in cancer therapy. We will improve the pharmacokinetics of the compound based on our model of the ternary Aurora-PROTAC-CEREBLON complex. We will use this optimized PROTAC to explore the efficacy and safety Aurora-A PROTACs in pre-clinical leukaemia models. At the same time, we will use our compounds to obtain a better understanding of the scaffolding role of Aurora-A regulating the cell cycle.In a second line of experiments, we will develop PROTACs for the promising cancer targets RUVBL1 and RUVB2. As Aurora-A, RUVBL proteins directly bind the onco-protein MYC and are indispensable for MYC´s oncogenic function. Moreover, and again similar to Aurora-A, both proteins bind and hydrolyse ATP, but have additional important oncogenic functions that are independent from their catalytic activity. Building on our experience with Aurora-A PROTACs, we will design, synthesize and characterize RUVBL1/2 PROTACs and test their anti-cancer properties in leukaemia models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploration of SIK2-signaling in ovarian cancer with CCNE1-amplification3
-
批准号:397659447
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Professor Dr. Stefan Knapp
-
依托单位:
Biochemical and structural studies on LRRK2 regulation.
-
批准号:407661177
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Professor Dr. Stefan Knapp
-
依托单位:
海外基金